Neurotech to enter next phase of implant testing

LINCOLN – Biotechnology firm Neurotech Pharmaceuticals Inc. is ready to begin the next phases of testing on its NT-501 for the treatment of retinitis pigmentosa. NT-501 is an implant containing cells genetically modified to secrete ciliary neurotrophic factor, a protein that stimulates cell growth, directly into the back of the eye for sustained periods of…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -